News|Articles|February 13, 2019

Elzonris for Blastic Plasmacytoid Dendritic Cell Neoplasm

Author(s)Drew Boxler

ELZONRIS (tagraxofusp-erzs, Stemline® Therapeutics)

Indications: Treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older

Dosage: Intravenously at 2mcg/kg over 15 mins once daily on days 1 & 5 of a 21-day cycle

  • First cycle recommended in inpatient setting, subsequent cycles either inpatient or other appropriate outpatient setting

Contraindications: None

Click here for more prescribing information

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.


Latest CME